Mark A. Schallenberger - 15 Nov 2025 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Reporting relationship: Chief Operating Officer
Issuer ticker: XTNT
Reported as of: 15 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Nov 2025, 16:55:10 UTC
Prior SEC filing: 17 Jan 2025
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Culbert, attorney-in-fact

Key filing fact

Mark A. Schallenberger filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 18 Nov 2025.

Key facts

This page summarizes Mark A. Schallenberger's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Nov 2025, 16:55.

Change

Previous filing in this sequence was filed on 17 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001960742 Primary reporting owner

Schallenberger Mark A.

Relationship: Chief Operating Officer
Address: C/O XTANT MEDICAL HOLDINGS, INC., 664 CRUISER LANE, BELGRADE
Signature: /s/ Amy Culbert, attorney-in-fact
Signature date: 18 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock

Award

Transaction value: $0
Shares: +292,253
Change %: +77%
Price: $0.000000
Shares after: 670,866
Date: 15 Nov 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XTNT transaction Derivative

Performance Stock Units (PSUs)

Award

Transaction value: $0
Shares: +584,506
Change %
Price: $0.000000
Shares after: 584,506
Date: 15 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 584,506
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares will vest with respect to 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and with respect to 73,064 shares on November 5, 2029 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Includes an aggregate of 523,794 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 44,500 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

Footnote F3

Each PSU represents a contingent right to receive one share of the Issuer's common stock. The PSUs will vest and become earned in one-third increments based on the achievement of specified stock price performance goals during a three-year performance period and subject to additional service-based vesting conditions.

Footnote F4

Represents the maximum number of shares that may be issued pursuant to the PSUs, which is 200% of the target number of shares (292,253).